Differential Activity of PARP Inhibitors in < em > BRCA1 < /em > - Versus < em > BRCA2 < /em > -Altered Metastatic Castration-Resistant Prostate Cancer

CONCLUSION: PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.PMID:34778690 | PMC:PMC8575434 | DOI:10.1200/PO.21.00070

Source: Ann Oncol - November 15, 2021 Category: Cancer & Oncology Authors: Fadi Taza Albert E Holler Wei Fu Hao Wang Nabil Adra Costantine Albany Ryan Ashkar Heather H Cheng Alexandra O Sokolova Neeraj Agarwal Adam Kessel Alan Bryce Nellie Nafissi Pedro Barata A Oliver Sartor Diogo Bastos Oren Smaletz Jacob E Berchuck Mary-Ellen Source Type: research